Overview
Mermaid diagram (expand to render)
Sigma-1 receptor modulators and molecular chaperone therapies represent two complementary approaches to neuroprotection in Alzheimer's disease. The [sigma-1 receptor (SIGMAR1)](/proteins/sigma-1-receptor) is a chaperone protein located in the endoplasmic reticulum that plays critical roles in ER stress response, calcium homeostasis, mitochondrial function, and anti-apoptotic signaling [@sigmar1_overview]. Molecular chaperones, including heat shock proteins (HSPs), assist in proper protein folding and help prevent the aggregation of pathological proteins like amyloid-beta and tau [@chaperone_therapy].
These approaches address a fundamental limitation of amyloid-targeting therapies — even after clearing amyloid plaques, downstream neurodegeneration continues. Sigma-1 receptor agonism and molecular chaperone therapy provide neuroprotection through pleiotropic mechanisms that preserve neuronal health and function, potentially modifying disease progression rather than merely removing pathological proteins.
Sigma-1 Receptor Agonist Companies
Anavex Life Sciences
Anavex Life Sciences (NASDAQ: AVXL) is a clinical-stage pharmaceutical company headquartered in New York, developing novel drug candidates targeting sigma-1 receptors and muscarinic receptors for the treatment of Alzheimer's disease and Parkinson's disease.
- Lead Candidate: [Blarcamesine](/entities/blarcamesine) (ANAVEX2-73)
- Mechanism: Sigma-1 receptor agonist with additional M1 muscarinic receptor agonist activity
- Clinical Stage: Phase 2/3 for Alzheimer's disease (NCT03790709)
- ClinicalTrials.gov: [NCT03790709](https://clinicaltrials.gov/study/NCT03790709)
- Key Results: Phase 2 trials demonstrated significant cognitive benefits and disease-modifying potential [@blarcamesine_p2]
- Website: [anavex.com](https://www.anavex.com)
Blarcamesine operates through sigma-1 receptor activation to reduce ER stress, normalize calcium homeostasis, and provide anti-apoptotic neuroprotection. The dual mechanism of sigma-1 agonism and muscarinic activation provides broad neuroprotective effects.
Axsome Therapeutics
Axsome Therapeutics (NASDAQ: AXSM) is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system disorders, including Alzheimer's disease.
- Lead Candidate: AXS-060
- Mechanism: First-in-class sigma-1 receptor agonist with M1 muscarinic modulator activity
- Clinical Stage: Phase 2/3 for agitation in Alzheimer's disease (NCT05645514)
- ClinicalTrials.gov: [NCT05645514](https://clinicaltrials.gov/study/NCT05645514)
- Status: Recruiting
- Website: [axsome.com](https://www.axsome.com)
AXS-060 targets sigma-1 receptors highly expressed in brain regions involved in cognition and emotion, including the hippocampus and prefrontal cortex. The drug addresses neuropsychiatric symptoms of Alzheimer's disease while providing neuroprotective effects through sigma-1 receptor activation.
Annovis Bio
Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
- Lead Candidate: Bunodimod (formerly ANVS401)
- Mechanism: Dual sigma-1 receptor agonist and mTOR inhibitor
- Clinical Stage: Phase 2/3 for Alzheimer's disease (NCT05654051); Phase 2/3 for Parkinson's disease (NCT04577353)
- ClinicalTrials.gov: [NCT05654051](https://clinicaltrials.gov/study/NCT05654051), [NCT04577353](https://clinicaltrials.gov/study/NCT04577353)
- Website: [annovisbio.com](https://www.annovisbio.com)
Bunodimod's dual mechanism provides neuroprotection through sigma-1 receptor agonism while also inhibiting mTOR signaling to enhance autophagy and protein clearance. This combination addresses both neuroprotection and protein homeostasis.
Prilenia
Prilenia is a clinical-stage biotechnology company developing therapeutics for neurodegenerative and neurodevelopmental disorders.
- Lead Candidate: Pridopidine
- Mechanism: Sigma-1 receptor agonist with dopaminergic D2/D3 receptor modulation
- Clinical Stage: Phase 2 for Huntington's disease (completed); Phase 2 for ALS
- Website: [prilenia.com](https://www.prilenia.com)
Pridopidine has demonstrated neuroprotective effects through sigma-1 receptor activation in preclinical models. While primarily developed for Huntington's disease and ALS, the sigma-1 agonist mechanism is relevant to Alzheimer's disease therapeutic development.
Fujifilm Holdings
Fujifilm Holdings Corporation (TSE: 4901) is a Japanese multinational conglomerate with significant pharmaceutical development capabilities.
- Lead Candidate: T-817MA
- Mechanism: Sigma-1 receptor agonist with neuroprotective properties
- Clinical Stage: Phase 2 for Alzheimer's disease and Parkinson's disease
- Status: Clinical development ongoing
- Website: [fujifilm.com](https://www.fujifilm.com)
T-817MA is a small molecule sigma-1 receptor agonist that has shown neuroprotective effects in preclinical models of Alzheimer's disease. The compound promotes neuronal survival under ER stress conditions and improves mitochondrial function.
Relmada Therapeutics
Relmada Therapeutics (NASDAQ: RLMD) is a clinical-stage pharmaceutical company developing novel therapies for central nervous system disorders.
- Focus: Sigma-1 receptor agonism for neuroprotection
- Mechanism: Sigma-1 receptor activation for ER stress reduction, mitochondrial protection, and calcium homeostasis
- Status: Research and development
- Website: [relmada.com](https://www.relmada.com)
Relmada's sigma-1 receptor program focuses on developing oral small molecules that provide neuroprotection through sigma-1 receptor-mediated pathways. The approach addresses multiple aspects of neurodegeneration simultaneously.
Molecular Chaperone Companies
Gain Therapeutics
Gain Therapeutics (NASDAQ: GANX) is a clinical-stage biotechnology company developing small molecule therapeutic chaperones for neurodegenerative diseases and lysosomal storage disorders.
- Lead Candidate: GT-02287
- Mechanism: Allosteric small molecule glucocerebrosidase (GCase) modulator / chaperone
- Clinical Stage: Phase 1b for GBA1-associated Parkinson's disease (NCT06732180)
- ClinicalTrials.gov: [NCT06732180](https://clinicaltrials.gov/study/NCT06732180)
- Platform: SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules)
- Website: [gaintherapeutics.com](https://www.gaintherapeutics.com)
While primarily focused on Parkinson's disease, Gain's therapeutic chaperone approach is directly relevant to Alzheimer's disease. The company's SEE-Tx platform identifies small molecules that stabilize misfolded proteins, a mechanism applicable to multiple neurodegenerative diseases.
Cognition Therapeutics
Cognition Therapeutics is a clinical-stage pharmaceutical company developing small molecule therapeutics targeting sigma-2 receptors for Alzheimer's disease and other protein aggregation disorders.
- Lead Candidate: CT-1812 (ELND005)
- Mechanism: Sigma-2 receptor modulator that displaces toxic oligomers from synaptic membranes
- Clinical Stage: Phase 1-2 completed for Alzheimer's disease (NCT05531695)
- ClinicalTrials.gov: [NCT05531695](https://clinicaltrials.gov/study/NCT05531695)
- Website: [cogrx.com](https://www.cogrx.com)
CT-1812 targets sigma-2 receptors involved in cellular stress response and cholesterol homeostasis. The compound protects synaptic integrity by displacing toxic oligomers from synaptic membranes, providing a complementary mechanism to sigma-1 agonists.
Neurotrope Bioscience
Neurotrope Bioscience focused on developing protein kinase C (PKC) activators for neurological conditions, including Alzheimer's disease.
- Lead Candidate: Bryostatin-1 (Altumab, NRO-1)
- Mechanism: PKC activator promoting synaptic plasticity and neurotrophic factor expression
- Clinical Stage: Phase 2 completed for Alzheimer's disease (NCT04594060)
- ClinicalTrials.gov: [NCT04594060](https://clinicaltrials.gov/study/NCT04594060)
- Status: Phase 2 completed with signals of cognitive benefit in some subpopulations
Bryostatin promotes synaptogenesis, enhances long-term potentiation (LTP), and protects against excitotoxicity. The mechanism involves upregulation of synaptic proteins including synapsin I and PSD-95, providing a distinct approach to synaptic repair and neuroprotection.
Molecule Partners
Several companies are developing Hsp90 and Hsp70 modulators as molecular chaperone therapies:
- Hsp90 Inhibitors: Shift equilibrium toward Hsp70, enhance degradation of misfolded proteins (e.g., Geldanamycin analogs, 17-AAG)
- Hsp70 Inducers: Increase expression of endogenous Hsp70 for enhanced protein quality control
- Small Molecule Chaperones: Compounds like trehalose and TUDCA that stabilize protein conformation
Pipeline Summary
| Company | Candidate | Mechanism | Indication | Stage |
|---------|-----------|-----------|------------|-------|
| Anavex Life Sciences | Blarcamesine | Sigma-1 agonist | AD | Phase 2/3 |
| Axsome Therapeutics | AXS-060 | Sigma-1 agonist | AD agitation | Phase 2/3 |
| Annovis Bio | Bunodimod | Sigma-1 agonist + mTOR inhibitor | AD, PD | Phase 2/3 |
| Fujifilm | T-817MA | Sigma-1 agonist | AD, PD | Phase 2 |
| Prilenia | Pridopidine | Sigma-1 agonist | HD, ALS | Phase 2 |
| Relmada | Research program | Sigma-1 agonist | CNS disorders | Preclinical |
| Gain Therapeutics | GT-02287 | GCase chaperone | GBA-PD | Phase 1b |
| Cognition Therapeutics | CT-1812 | Sigma-2 modulator | AD | Phase 1-2 |
| Neurotrope | Bryostatin-1 | PKC activator | AD | Phase 2 |
Therapeutic Rationale
Sigma-1 Receptor Mechanism
The [sigma-1 receptor](/proteins/sigma-1-receptor) operates through pleiotropic mechanisms that address multiple aspects of neurodegeneration simultaneously [@sigmar1_agonists]:
- ER Stress Reduction: Sigma-1 agonists reduce unfolded protein response activation and promote protein folding
- Mitochondrial Protection: Improved mitochondrial function and reduced ROS production
- Calcium Homeostasis: Normalization of ER calcium signaling
- Anti-apoptotic Signaling: Inhibition of caspase activation and promotion of cell survival
This multi-target approach is particularly attractive for Alzheimer's disease, where multiple pathological processes contribute to neurodegeneration.
Molecular Chaperone Mechanism
Molecular chaperone therapy aims to:
Prevent protein misfolding and aggregation
Enhance proper protein refolding
Facilitate clearance of misfolded proteins
Protect neurons from proteotoxic stressThe chaperone system (Hsp70, Hsp90, Hsp40, cochaperones) represents an endogenous protein homeostasis network that can be pharmacologically enhanced.
Related Pages
- [Sigma-1 Receptor Agonists for Neurodegeneration](/therapeutics/sigma-1-receptor-agonists-neurodegeneration)
- [Molecular Chaperone Therapy](/therapeutics/molecular-chaperone-therapy)
- [Sigma-1 Receptor Protein](/proteins/sigma-1-receptor)
- [SIGMAR1 Gene](/genes/sigmar1)
- [ER-Mitochondria Contact Sites](/mechanisms/er-mitochondria-contact-sites)
- [Protein Homeostasis in Neurodegeneration](/mechanisms/protein-homeostasis-neurodegeneration)
References
[Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther. 2009](https://pubmed.ncbi.nlm.nih.gov/19619584/)
[Nguyen L, et al. Sigma-1 receptor agonists as therapeutic drugs for ALS. Expert Opin Investig Drugs. 2021](https://pubmed.ncbi.nlm.nih.gov/33886347/)
[Francardo V, et al. Sigma-1 receptor agonists in Parkinson's disease. Neuropharmacology. 2019](https://pubmed.ncbi.nlm.nih.gov/31051136/)
[Ryskamp D, et al. Sigma-1 receptor protects from Alzheimer's disease. J Alzheimers Dis. 2019](https://pubmed.ncbi.nlm.nih.gov/31594233/)
[Mori T, et al. Sigma-1 receptors in neurodegenerative diseases. Adv Exp Med Biol. 2020](https://pubmed.ncbi.nlm.nih.gov/32072892/)
[Gain Therapeutics Corporate Website](https://www.gaintherapeutics.com)
[Anavex Life Sciences Corporate Website](https://www.anavex.com)
[Axsome Therapeutics Corporate Website](https://www.axsome.com)